TrakCel, UK-based software developer for cell and gene therapy supply chain tracking and orchestration, has appointed Joe Vitale Director of Process Engineering.
The appointment comes on the back of TrakCel’s recent announcement that it has opened its second US office in New Jersey, led by Rob Margolin, to support ambitious growth plans.
Vitale joins from PCT, a Caladrius Company, where he was a Senior Biomedical Engineer, focused on process optimisation for cellular therapy products and acting as expert for several T-cell Immunotherapy clinical processes.
He earned his BA in Biochemistry and Psychology at Montclair State University and his PhD from Rutgers University. His graduate studies focused on the use of pluripotent stem cells for the treatment of muscular dystrophy.
Following his graduate studies, Vitale carried out his post-doctoral studies at Mount Sinai School of Medicine, in the Department of Hematology and Medical Oncology, where he focused on hematopoietic erythroid differentiation.
Vitale said: “During the last five years, TrakCel has made significant strides in becoming the leading provider of needle-to-needle cell orchestration technology to aid the delivery of regenerative therapies. Its technology has helped industry leaders improve the efficiency and reliability of their products.”
“The company is rapidly growing as the industry is increasingly recognising the need to track and control therapies across multiple stakeholders, so I’m joining at a pivotal time in this corporate journey.”
Ravi Nalliah, Chief Executive Officer at TrakCel, said: “Joe has a vast amount of experience and understanding from the front-line of the cell and gene therapy industry – knowledge that will be extremely beneficial when we are liaising with clients from these industries.
“Joe understands exactly what our clients are looking for and will be able to communicate these requirements to our IT teams, ensuring our software platform provides optimum product traceability and control that exactly matches our customers’ needs.”
